- Home
- ELAN
as of 12-12-2025 3:41pm EST
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
| Founded: | 1954 | Country: | United States |
| Employees: | N/A | City: | GREENFIELD |
| Market Cap: | 10.3B | IPO Year: | 2018 |
| Target Price: | $22.11 | AVG Volume (30 days): | 5.0M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.07 | EPS Growth: | -82.84 |
| 52 Week Low/High: | $8.02 - $23.70 | Next Earning Date: | 11-05-2025 |
| Revenue: | $4,591,000,000 | Revenue Growth: | 3.08% |
| Revenue Growth (this year): | 7.19% | Revenue Growth (next year): | 5.32% |
AI-Powered ELAN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare ELAN vs Leading Stocks
See how ELAN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ELAN Elanco Animal Health Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.